18 September 2025 - Opzelura is the first topical Janus kinase inhibitor approved in the US for paediatric atopic dermatitis.

Incyte today announced that the US FDA has approved Opzelura (ruxolitinib) cream 1.5%, a topical Janus kinase inhibitor, for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised children two years of age and older whose disease is not well controlled with topical prescription therapies, or when those therapies are not recommended.

Read Incyte press release